Supernus Pharma (NASDAQ: SUPN) reported Q3 EPS of $0.40, $0.17 better than the analyst estimate of $0.23. Revenue for the quarter came in at $148.5 million versus the consensus estimate of $142.12 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.